ARCHER: ANX007 Mitigates Visual Acuity Loss in Geographic Atrophy
In the Phase 2 ARCHER trial, ANX007 protected against visual acuity loss and remained well-tolerated for patients with geographic atrophy.
In the Phase 2 ARCHER trial, ANX007 protected against visual acuity loss and remained well-tolerated for patients with geographic atrophy.
An airlines paper by experts asserts there’s no need for in-flight allergy PA announcements. Now clickbait headlines are triggering allergy misinformation.
This nervous system disorder causes a range of symptoms — and while there’s no cure, it’s possible to have long periods of remission.
How vaginal lactobacilli promote health and reduce inflammation remains unclear. Glick, Webber et al. identify a family of anti-inflammatory compounds produced by vaginal lactobacilli. β-carbolines suppress…
The 48-year-old Scot says doctors have told him he has between two and four years to live.
Document from the Ontario Medical Association reveals doctors have called 911 to get access to medical supplies
The Artemis program — years behind schedule and billions over budget — should have taxpayers and presidents demanding answers.
Amazon is using a new, proprietary AI solution called Vision-Assisted Package Retrieval (VAPR) to locate packages in its vans.
Being a patient can feel alien to many doctors and can bring unique challenges. Jo Best reports For many doctors who start their medical careers…
No comment from the U.S. Department of Commerce and Huawei
Each month, the AMA Medical Student Outreach Program (MSOP) identifies one event to highlight as the Section Involvement Grant Event of the Month. Find out…